Dextrose modified bilosomes for peroral delivery: improved therapeutic potential and stability of silymarin in diethylnitrosamine-induced hepatic carcinoma in rats

References

• Calvaresi, E.C., and Hergenrother, P.J., 2013. Glucose conjugation for the specific targeting and treatment of cancer. Chemical science, 4 (6), 2319–2333.
   PubMed Web of Science ®Google Scholar
• Che, L., et al., 2017. Oncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma. Cell cycle (Georgetown, Tex.), 16 (6), 499–507.
   PubMed Web of Science ®Google Scholar
• Davis, M.E., Chen, Z., and Shin, D.M., 2008. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nature reviews of drug discovery, 7(9), 771–782.
   PubMed Web of Science ®Google Scholar
• Davis, M.E., Chen, Z., and Shin, D.M., 2010. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nanoscience and technology: a collection of reviews from nature journals, world scientific, 239–250.
   Google Scholar
• De Minicis, S., et al., 2013. Liver carcinogenesis: rodent models of hepatocarcinoma and cholangiocarcinoma. Digestive and liver disease: official journal of the Italian society of gastroenterology and the Italian association for the study of the liver, 45 (6), 450–459.
   PubMedGoogle Scholar
• Elnaggar, Y.S., 2015. Multifaceted applications of bile salts in pharmacy: an emphasis on nanomedicine. International journal of nanomedicine, 10, 3955.
   PubMed Web of Science ®Google Scholar
• Fernando, L.P., et al., 2010. Mechanism of cellular uptake of highly fluorescent conjugated polymer nanoparticles. Biomacromolecules, 11 (10), 2675–2682.
   PubMed Web of Science ®Google Scholar
• Gebril, A.M., et al., 2014. Assessment of the antigen-specific antibody response induced by mucosal administration of a GnRH conjugate entrapped in lipid nanoparticles. Nanomedicine, Nanotechnology, Biology and Medicine, 10 (5), e971–e979.
   PubMed Web of Science ®Google Scholar
• Gorad, R.S., Mandlik, S.K., and Gujar, K.N., 2013. Liver specific drug targeting strategies: a review. International Journal of Pharmaceutical Sciences and Research, 11, 4145–4157.
   Google Scholar
• Guan, P., et al., 2011. Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt. International journal of nanomedicine, 6, 965.
   PubMed Web of Science ®Google Scholar
• Gupta, S., Singh, S.K., and Girotra, P., 2014. Targeting silymarin for improved hepatoprotective activity through chitosan nanoparticles. International journal of pharmaceutical investigation, 4 (4), 156.
   PubMedGoogle Scholar
• Jain, S., et al., 2014. Improved stability and immunological potential of tetanus toxoid containing surface engineered bilosomes following oral administration. Nanomedicine nanotechnolgy, biology and medicine, 10 (2), 431–440.
   PubMed Web of Science ®Google Scholar
• Kaithwas, G., and Majumdar, D.K., 2012. In vitro antioxidant and in vivo antidiabetic, antihyperlipidemic activity of linseed oil against streptozotocin‐induced toxicity in albino rats. European journal of lipid science and technology, 114 (11), 1237–1245.
   Web of Science ®Google Scholar
• Křen, V., and Walterova, D., 2005. Silybin and silymarin–new effects and applications. Biomedical papers, 149 (1), 29–41.
   PubMedGoogle Scholar
• Kumar, P., et al., 2017. 6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid attenuates heptatocellular carcinoma in rats with NMR-based metabolic perturbations. Future science OA, 3 (3), FSO202.
   PubMed Web of Science ®Google Scholar
• Lahiri-Chatterjee, M., et al., 1999. A flavonoid antioxidant, silymarin, affords exceptionally high protection against tumor promotion in the SENCAR mouse skin tumorigenesis model. Cancer research, 59 (3), 622–632.
   PubMed Web of Science ®Google Scholar
• Lammers, T., Hennink, W., and Storm, G., 2008. Tumour-targeted nanomedicines: principles and practice. British journal of cancer, 99 (3), 392.
   PubMed Web of Science ®Google Scholar
• Li, X., et al., 2010. Development of silymarin self-microemulsifying drug delivery system with enhanced oral bioavailability. AAPS PharmSciTech, 11 (2), 672–678.
   PubMed Web of Science ®Google Scholar
• Mahajan, S., and Mahajan, R.K., 2012. Interactions of phenothiazine drugs with bile salts: micellization and binding studies. Journal of colloid and interface science, 387 (1), 194–204.
   PubMedGoogle Scholar
• Mann, J.F., et al., 2006. Oral delivery of tetanus toxoid using vesicles containing bile salts (bilosomes) induces significant systemic and mucosal immunity. Methods (San Diego, Calif.), 38 (2), 90–95.
   PubMed Web of Science ®Google Scholar
• Morazzoni, P., et al., 1993. Comparative pharmacokinetics of silipide and silymarin in rats. European journal of drug metabolism and pharmacokinetics, 18 (3), 289–297.
   PubMed Web of Science ®Google Scholar
• Niu, M., et al., 2012. Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: the effect of cholate type, particle size and administered dose. European journal of pharmaceutics and biopharmaceutics : official journal of arbeitsgemeinschaft fur pharmazeutische verfahrenstechnik e.V, 81 (2), 265–272.
   PubMed Web of Science ®Google Scholar
• Parashar, P., et al., 2018a. A synergistic approach for management of lung carcinoma through folic acid functionalized co-therapy of capsaicin and gefitinib nanoparticles: enhanced apoptosis and metalloproteinase-9 down-regulation. Phytomedicine, 53, 107–123.
   PubMed Web of Science ®Google Scholar
• Parashar, P., et al., 2018b. Hyaluronic acid decorated naringenin nanoparticles: appraisal of chemopreventive and curative potential for lung cancer. Pharmaceutics, 10 (1), 33.
   PubMed Web of Science ®Google Scholar
• Peer, D., et al., 2007. Nanocarriers as an emerging platform for cancer therapy. Nature nanotechnology, 2 (12), 751.
   PubMed Web of Science ®Google Scholar
• Pitot, H.C., and Dragan, Y., 1991. Facts and theories concerning the mechanisms of carcinogenesis. FASEB journal: official publication of the federation of American societies for experimental biology, 5 (9), 2280–2286.
   PubMed Web of Science ®Google Scholar
• Senior, K., 2001. Bilosomes: the answer to oral vaccine delivery?. Drug discovery. Today, 6 (20), 1031–1032.
   PubMed Web of Science ®Google Scholar
• Sharma, M., et al., 2016. Design of folic acid conjugated chitosan nano-cur–bioenhancers to attenuate the hormone-refractory metastatic prostate carcinoma by augmenting oral bioavailability. RSC advances, 6 (30), 25137–25148.
   Web of Science ®Google Scholar
• Shegokar, R., and Singh, K.K., 2012. Preparation characterization and cell based delivery of stavudine surface modified lipid nanoparticles. Journal of nanomedicine and biotherapeutic discovery, 2 (3), 1–9.
   PubMedGoogle Scholar
• Shukla, A., et al., 2010a. M-cell targeted delivery of recombinant hepatitis B surface antigen using cholera toxin B subunit conjugated bilosomes. International journal of pharmaceutics, 385 (1-2), 47–52.
   PubMed Web of Science ®Google Scholar
• Shukla, A., et al., 2010b. Nano-bilosomes as potential vaccine delivery system for effective combined oral immunization against tetanus and hepatitis B. Journal of biotechnology, 150 (150), 98–99.
   Google Scholar
• Singh, P., et al., 2016a. Design of topical nanostructured lipid carrier of silymarin and its effect on 7, 12-dimethylbenz [a] anthracene (DMBA) induced cellular differentiation in mouse skin. RSC advances, 6 (88), 84965–84977.
   Web of Science ®Google Scholar
• Song, K.-H., Chung, S.-J., and Shim, C.-K., 2005. Enhanced intestinal absorption of salmon calcitonin (sCT) from proliposomes containing bile salts. Journal of controlled release: official journal of the controlled release society, 106 (3), 298–308.
   PubMed Web of Science ®Google Scholar
• Vila, A., et al., 2002. Design of biodegradable particles for protein delivery. Journal of controlled release, 78 (1–3), 15–24.
   PubMed Web of Science ®Google Scholar
• Wilkhu, J., et al., 2011. Formulation design considerations for oral vaccines. Therapeutic delivery, 2 (9), 1141–1164.
   PubMedGoogle Scholar
• Wilkhu, J.S., et al., 2013. Characterization and optimization of bilosomes for oral vaccine delivery. Journal of drug targeting, 21 (3), 291–299.
   PubMed Web of Science ®Google Scholar
• Yan, H., et al., 2015. Targeting C-type lectin receptors for cancer immunity. Frontiers in immunology, 6, 408.
   PubMed Web of Science ®Google Scholar
• Yu, JN., et al., 2010. Enhancement of oral bioavailability of the poorly water-soluble drug silybin by sodium cholate/phospholipid-mixed micelles. Acta pharmacologica sinica, 31 (6), 759.
   PubMed Web of Science ®Google Scholar